Synonym name: Eleutheroside M; Hederacoside B; Hederacolchiside C; Tauroside G2; Glycoside L-G2; Akebasaponin PJ3; Kizutasaponin K12
Catalogue No.: BP0711
Cas No.: 36284-77-2
Formula: C₅₉H₉₆O₂₅
Mol Weight: 1205.39
Botanical Source: Eleutherococcus (Acanthopanax) senticosus (Siberian ginseng), Hedera colchica, Hedera conariensis and Hedera taurica

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
Can be supplied from milligrams to grams.

For Reference Standard and R&D, Not for Human Use Directly.
Inquire for bulk scale.

HPLC of Hederasaponin B

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Hederasaponin B is a natural triterpene saponin compound isolated from hedera helix. In recent years, as the importance of natural products in drug development has become increasingly prominent, ivy saponin B has gradually become a research hotspot due to its unique chemical structure and diverse biological activities, especially its broad-spectrum antiviral activity against enterovirus 71 (EV71) and its various subtypes. Moreover, an increasing number of studies reveal its potential therapeutic value in various diseases such as breast cancer, involving multiple key molecular targets. This paper aims to systematically review the chemical structure, pharmacological activity, mechanism of action, druggability evaluation, and clinical application prospects of Ivy Saponin B, aiming to provide a theoretical basis and research direction for its subsequent drug development and clinical translation.

Chemical structure and physicochemical properties

Ivy saponin B has a molecular formula of C58H92O26 and a molecular weight of 1205.3920, making it a typical triterpene saponin compound. Its structural core is a pentacyclic triterpene backbone, connecting multiple glycosidic groups to form a complex glycan structure. The compound has a LogP value of 2.3168, indicating moderate lipid solubility, which facilitates cell membrane penetration and bioavailability. The total polar surface area (TPSA) reaches as high as 392.59 Ų, indicating strong molecular polarity that may affect its transmembrane transport and absorption characteristics. Water solubility is 0.2212, making it a low-soluble compound, suggesting that solubility improvement strategies should be considered in drug formulation design. The blood-brain barrier has low permeability, indicating limited distribution in the central nervous system. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. The Ames-induced mutagenic test result was 0.0, indicating a low genotoxicity risk and a solid safety foundation.

Plant Origins and Extraction Methods

Ivy saponin B mainly originates from the leaves and stems of ivy (Hedera helix). Ivy is an evergreen climbing plant widely distributed across Europe, Asia, and parts of North America. Its leaves are rich in triterpene saponins, which are the main raw material for extracting ivy saponin B.

The extraction process typically uses solvent extraction combined with chromatographic separation. First, after drying, the ivy leaves are crushed and extracted by reflux with ethanol or methanol. After concentration, the extract is distributed using a water-ethanol gradient solvent to remove fat-soluble impurities. Subsequently, technologies such as silica gel column chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC) were used to separate and purify the extracts, ultimately obtaining high-purity ivy saponin B. In recent years, the application of ultrasound-assisted extraction and microwave-assisted extraction technologies has improved extraction efficiency and purity, while reducing production costs.

Pharmacological activity research

Antiviral activity

Ivy saponin B exhibited significant inhibitory effects on enterovirus 71 (EV71) and various subtypes. EV71 is the main pathogen causing hand, foot, and mouth disease and severe neurological complications, and there is a lack of effective, specific antiviral drugs. In vitro cell experiments have shown that ivy saponin B can effectively reduce the replication and infection ability of the EV71 virus, inhibiting virus-related cellular lesions. Its antiviral activity is broad-spectrum and has low cytotoxicity, demonstrating good therapeutic potential.

Antitumor activity

In recent years, research on ivy saponin B in the field of breast cancer has been gradually deepening. Multiple in vitro and in vivo experiments have shown that ivy saponin B can inhibit the proliferation, migration, and invasion of breast cancer cells by regulating multiple signaling pathways, thereby inducing apoptosis. Its effects involve regulating the cell cycle, inhibiting the expression of tumor-related matrix-degrading enzymes (such as MMP2), and influencing immune cell function within the tumor microenvironment.

Anti-inflammatory and immunomodulatory effects

Ivy saponin B has certain anti-inflammatory activity, inhibiting the release of inflammatory factors such as TNF-α and IL-6, thereby reducing inflammatory responses. Moreover, its regulatory effect on immune cell function also provides a theoretical basis for its application in immune-related diseases.

Mechanism of action and molecular targets

The biological activity of ivy saponin B mainly relies on regulating various molecular targets and signaling pathways, with a particularly well-defined mechanism in breast cancer treatment.

1. AMPK (PRKAA1) activates
   AMPK, as a key regulator of cellular energy metabolism, Ivy saponin B can activate the AMPK signaling pathway, promote disruption of tumor cell energy metabolism, and inhibit its proliferation and survival.

2. BCL2 family proteins are regulated
   By downregulating the expression of the anti-apoptotic protein BCL2, ivy saponin B promotes apoptosis in breast cancer cells and enhances the sensitivity of chemotherapy drugs.

3. STAT3 signaling pathway inhibition
   STAT3 is an important regulatory factor for tumor cell proliferation and immune evasion. Ivy saponin B inhibits STAT3 phosphorylation and nuclear translocation, blocking its transcriptional activity and suppressing tumor progression.

4. Regulation of estrogen receptor β (ESR2).
   By regulating ESR2, Ivy Saponin B influences the hormone-dependent growth of breast cancer cells and exerts anti-tumor effects.

5. Inhibition of multidrug resistance-related proteins (ABCB1, ABCG2).
   Ivy saponin B can inhibit the expression of ABCB1 and ABCG2 in tumor cells, reverse multidrug resistance, and enhance the efficacy of chemotherapy drugs.

6. Protein kinase Cα (PRKCA) and microtubule-related protein Tau (MAPT) are regulated
   By modulating PRKCA and MAPT, Ivy Saponin B affects cytoskeletal stability and signal transduction, inhibiting tumor cell migration and invasion.

7. Matrix metalloproteinase 2 (MMP2) inhibition
   MMP2 is involved in the degradation and metastasis of tumor cell stromal processes, while ivy saponin B inhibits its expression and prevents tumor metastasis.

8. LCK kinase regulation
   LCK, as a key tyrosine kinase in the T cell receptor signaling pathway, may regulate the regulatory effects of ivy saponin B on it, potentially affecting the tumor immune microenvironment and enhancing immune surveillance.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, ivy saponin B has certain advantages and challenges. Its molecular weight is relatively large (1205.3920), exceeding the range recommended by Lipinski's rules, which may limit oral absorption. A moderate LogP value (2.3168) favors cell membrane penetration, but a high TPSA (392.59) indicates strong polarity, which may reduce membrane permeability and oral bioavailability. Low water solubility (0.2212) suggests that formulation development should use solubilization or nanocarrier technologies to improve dissolution and absorption.

The blood-brain barrier has low permeability, reducing the risk of toxic side effects in the central nervous system, but limiting its application in neurological diseases. Negative hERG channel inhibitory results and negative Ames tests indicate good safety, with low risks of cardiotoxicity and genotoxicity.

Currently, pharmacokinetic data on ivy saponin B are relatively limited. Preliminary studies show that it has good metabolic stability in vivo but low oral bioavailability, mainly metabolized through the liver enzyme system, with excretion primarily via bile and feces. In the future, systematic pharmacokinetic and toxicological studies are needed to optimize dosing regimens and dosage form design.

Prospects and outlooks for clinical applications

As a natural product with broad-spectrum antiviral activity and antitumor potential, Ivy Saponin B has promising prospects for clinical translation. Its inhibitory effect on the EV71 virus provides new candidate drugs for the treatment of viral diseases such as hand, foot, and mouth disease. Especially in the context of frequent viral diseases worldwide, developing safe and effective antiviral drugs is of great significance.

In the field of tumor treatment, ivy saponin B regulates the proliferation and metastasis of breast cancer cells through multiple targets and pathways, demonstrating good anti-tumor activity. Its ability to reverse multidrug resistance offers new strategies to overcome chemotherapy resistance. In the future, combining targeted drugs with immunotherapy may further enhance clinical efficacy.

However, Ivy Saponin B has druggability limitations such as high molecular weight and low bioavailability, requiring improvement of pharmacokinetic properties through structural modification and nanocarrier encapsulation. In addition, systematic preclinical safety evaluation and clinical trial data remain lacking, which is a key bottleneck in their clinical application.

Future research should focus on the following aspects:
1. In-depth analysis of its antiviral and antitumor molecular mechanisms to uncover more potential targets.
2. Optimize extraction and purification processes to increase yield and purity, and reduce production costs.
3. Develop novel drug delivery systems to enhance oral bioavailability and targeting.
4. Improve pharmacokinetics and toxicology studies to ensure safety.
5. Conduct preclinical and clinical studies to verify efficacy and safety.

Conclusion

Ivy saponin B, as a natural triterpene saponin derived from ivy, demonstrates broad drug development potential due to its broad-spectrum antiviral activity and multi-target antitumor effects. Its unique chemical structure and diverse biological activities provide an important model for pharmacological research of natural products. Although challenges remain in druggability and clinical translationality, with deeper research and technological advancements, Ivy Saponin B is expected to become a novel candidate drug in the fields of antiviral and anti-tumor treatments. Future multidisciplinary collaborative research will move from the laboratory to clinical practice, bringing new hope for the treatment of related diseases.